What happened
Celltrion Pharm reported separate results for FY2025: revenue of US$367M (+12.3% year on year), operating profit of US$38.4M (+50.7% year on year) and net income of US$26.5M (+76.4% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$367M |
|---|---|
| Revenue vs a year earlier | +12.3% |
| Operating profit | US$38.4M |
| Net income | US$26.5M |
| Period | FY2025 (separate) |
| Filed | 2026-02-05, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260205900149 → open original filing |
Source: DART. Information only, not investment advice.